TY - JOUR
T1 - Reimagining Vaccines for Prostate Cancer
T2 - Back to the Future
AU - Shenderov, Eugene
AU - Antonarakis, Emmanuel S.
N1 - Funding Information:
This work was partially supported by National Institutes of Health Cancer Center support grant P30 CA006973 (to E. Shenderov and E.S. Antonarakis), Prostate Cancer Foundation Young Investigator Award (to E. Shenderov), Department of Defense grant W81XWH-16-PCRP-CCRSA (to E.S. Antonarakis) and grant W81XWH-19-1-0511 (to E. Shenderov), and the Bloomberg-Kimmel Institute for Cancer Immunotherapy (to E. Shenderov and E.S. Antonarakis).
Publisher Copyright:
©2020 American Association for Cancer Research.
PY - 2020/10/1
Y1 - 2020/10/1
N2 - Given the modest clinical benefits observed with immune checkpoint blockade in advanced prostate cancer, there is a renewed interest in exploring other forms of immunotherapy. Here, the authors report the use of a novel plasmid DNA vaccine encoding the androgen receptor, called pTVG-AR, in men with metastatic hormone-sensitive prostate cancer.
AB - Given the modest clinical benefits observed with immune checkpoint blockade in advanced prostate cancer, there is a renewed interest in exploring other forms of immunotherapy. Here, the authors report the use of a novel plasmid DNA vaccine encoding the androgen receptor, called pTVG-AR, in men with metastatic hormone-sensitive prostate cancer.
UR - http://www.scopus.com/inward/record.url?scp=85101021086&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101021086&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-20-2257
DO - 10.1158/1078-0432.CCR-20-2257
M3 - Review article
C2 - 32737029
AN - SCOPUS:85101021086
SN - 1078-0432
VL - 26
SP - 5056
EP - 5058
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 19
ER -